Larazotide dosage: reported doses and schedule

An oral gut-barrier peptide with mixed celiac results and a stopped phase 3 trial.

Also called: Larazotide acetate, AT-1001, AT1001, INN-202, NM-001.

Gut peptides · Oral tight-junction regulator; proposed zonulin-pathway antagonist.

Typical reported dose: 0.25 mg three times a day before meals

First celiac study: 12 mg: 12 mg per dose; Once daily once daily, by mouth. Studied in a trial. Studied in: Adults with controlled celiac disease. (source)
Healthy volunteers: 0.25 mg: 0.25 mg per dose; Three times daily three times daily, by mouth. Studied in a trial. Studied in: Healthy adults aged 18–45. (source)
Healthy volunteers: 1 mg: 1 mg per dose; Three times daily three times daily, by mouth. Studied in a trial. Studied in: Healthy adults aged 18–45. (source)
Healthy volunteers: 4 mg: 4 mg per dose; Three times daily three times daily, by mouth. Studied in a trial. Studied in: Healthy adults aged 18–45. (source)
Two-week gluten challenge: 0.25 mg: 0.25 mg per dose; Three times daily three times daily, by mouth. Studied in a trial. Studied in: Adults with celiac disease in remission. (source)
Two-week gluten challenge: 1 mg: 1 mg per dose; Three times daily three times daily, by mouth. Studied in a trial. Studied in: Adults with celiac disease in remission. (source)

Highest studied: 8 mg orally three times daily in gluten-challenge trials; 24 mg total per day..

These are doses reported in labels, trials or user reports, not a personal plan. Check the source behind each one.

Related to Larazotide

BPC-157: An experimental repair peptide with mostly animal evidence and a few small human reports.
KPV: An alpha-MSH fragment studied for gut inflammation in animals, with no human dosing trial.

Sources checked: 2026-10-18.

Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.